Terms: = Ovarian cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck AND Treatment
12 results:
1. A multimodal radiomic machine learning approach to predict the lck expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract] [Full Text] [Related]
2. lck facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract] [Full Text] [Related]
3. Pretreatment with lck inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors.
Crean-Tate KK; Braley C; Dey G; Esakov E; Saygin C; Trestan A; Silver DJ; Turaga SM; Connor EV; DeBernardo R; Michener CM; Rose PG; Lathia J; Reizes O
J Ovarian Res; 2021 Apr; 14(1):55. PubMed ID: 33888137
[TBL] [Abstract] [Full Text] [Related]
4. Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.
Ma J; Zhang JK; Yang D; Ma XX
Aging (Albany NY); 2020 Nov; 12(21):22152-22173. PubMed ID: 33159014
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.
Ayhan A; Akilli H
Int J Gynaecol Obstet; 2021 Feb; 152(2):202-207. PubMed ID: 33020918
[TBL] [Abstract] [Full Text] [Related]
6. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract] [Full Text] [Related]
7. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.
Fuh KC; Shin JY; Kapp DS; Brooks RA; Ueda S; Urban RR; Chen LM; Chan JK
Gynecol Oncol; 2015 Mar; 136(3):491-7. PubMed ID: 25455734
[TBL] [Abstract] [Full Text] [Related]
8. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
9. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Gallo D; Giacomelli S; Ferlini C; Raspaglio G; Apollonio P; Prislei S; Riva A; Morazzoni P; Bombardelli E; Scambia G
Eur J Cancer; 2003 Nov; 39(16):2403-10. PubMed ID: 14556934
[TBL] [Abstract] [Full Text] [Related]
10. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract] [Full Text] [Related]
12. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract] [Full Text] [Related]